ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Clinical Nurse Specialist, Psychiatric/Mental Health, Adult

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,483Medicare Part D Prescriptions Filled, Including Refills
$1.26M Total Retail Price of All Prescriptions
412 Patients Receiving at Least One Drug in Part D
12%Patients 65 Years and Older
95% Subsidized Claims for Low-Income Patients

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume .

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category
BENZTROPINE MESYLATE 692 75 R
RISPERIDONE 601 87
QUETIAPINE FUMARATE 438 37
LAMOTRIGINE 418 0
ABILIFY 371 24
OLANZAPINE 329 86
TRAZODONE HCL 278 36
FLUOXETINE HCL 271 12
CITALOPRAM HBR 246 52
DIVALPROEX SODIUM ER 238 14
DIVALPROEX SODIUM 231 40
CLOZAPINE 222 0
LITHIUM CARBONATE 220 20
SERTRALINE HCL 208 29
PAROXETINE HCL 197 49
SEROQUEL 196 20
ZOLPIDEM TARTRATE 164 13
HALOPERIDOL 149 20
ESCITALOPRAM OXALATE 141 29
CYMBALTA 136 0
BUPROPION HCL SR 129 16
INVEGA 128 18
FLUVOXAMINE MALEATE 116 0
BUPROPION XL 116 0
VENLAFAXINE HCL ER 115 18
RISPERDAL CONSTA 101 15
ZYPREXA 94 12
BUSPIRONE HCL 82 25
MIRTAZAPINE 79 13
ZALEPLON 76 14
FLUPHENAZINE HCL 74 0
CARBAMAZEPINE 74 0
GABAPENTIN 73 13
FANAPT 73 0
PROPRANOLOL HCL 70 0
AMPHETAMINE SALT COMBO 67 0 S2
TRIHEXYPHENIDYL HCL 66 0 R
CLOMIPRAMINE HCL 65 12 R
RISPERIDONE M-TAB 64 27
ZIPRASIDONE HCL 62 0
DEPAKOTE ER 56 0
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Aug. 13, 2014.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.